• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

群体药代动力学参数估计方法的评估。II. 双指数模型与实验药代动力学数据

Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.

作者信息

Sheiner L B, Beal S L

出版信息

J Pharmacokinet Biopharm. 1981 Oct;9(5):635-51. doi: 10.1007/BF01061030.

DOI:10.1007/BF01061030
PMID:7334463
Abstract

Individual pharmacokinetic parameters quantify the pharmacokinetics of an individual, while population pharmacokinetic parameters quantify population mean-kinetics, interindividual variability, and residual variability, including intraindividual variability and measurement error. Individual pharmacokinetics are estimated by fitting individual data to a pharmacokinetic model. Population pharmacokinetic parameters have been estimated either by fitting all individuals' data together as though there were no individual kinetic difference, the naive pooled data (NPD) approach, or by fitting each individuals' data separately and then combining the individual parameter estimates, the two stage (TS) approach. A third approach, NONMEM, takes a middle course between these. This study provides further evidence of NONMEM's validity by comparing, using simulation, the three approaches on three types of data sets corresponding to three typical types of pharmacokinetic studies. The estimates of population parameters provided by the NPD method are poorer than those provided by either of the other methods. The estimates provided by the TS method are adequate for mean values and for residual variability, but not for interindividual kinetic variability. NONMEM's estimates are as good as those of the TS method for mean parameters and for residual variability, and considerably better for interindividual variability. The latter estimates are still not acceptable in an absolute sense. This is probably due, not to an intrinsic fault of the method (as it is in the case of the TS approach), but to an insufficient number of individuals being studied.

摘要

个体药代动力学参数量化个体的药代动力学,而群体药代动力学参数则量化群体的平均动力学、个体间变异性和残余变异性,包括个体内变异性和测量误差。个体药代动力学通过将个体数据拟合到药代动力学模型来估计。群体药代动力学参数的估计方法有两种:一种是将所有个体的数据一起拟合,就好像不存在个体动力学差异一样,即单纯合并数据(NPD)法;另一种是分别拟合每个个体的数据,然后合并个体参数估计值,即两阶段(TS)法。第三种方法NONMEM则介于这两者之间。本研究通过模拟比较三种方法在对应于三种典型药代动力学研究类型的三种数据集上的表现,进一步证明了NONMEM的有效性。NPD方法提供的群体参数估计值比其他两种方法中的任何一种都要差。TS方法提供的估计值对于平均值和残余变异性是足够的,但对于个体间动力学变异性则不够。NONMEM对于平均参数和残余变异性的估计与TS方法一样好,对于个体间变异性的估计则明显更好。从绝对意义上讲,后者的估计值仍然不可接受。这可能不是由于该方法本身的缺陷(如TS方法那样),而是由于所研究的个体数量不足。

相似文献

1
Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.群体药代动力学参数估计方法的评估。II. 双指数模型与实验药代动力学数据
J Pharmacokinet Biopharm. 1981 Oct;9(5):635-51. doi: 10.1007/BF01061030.
2
Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.群体药代动力学参数估计方法的评价。III. 单指数模型:常规临床药代动力学数据
J Pharmacokinet Biopharm. 1983 Jun;11(3):303-19. doi: 10.1007/BF01061870.
3
Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.群体药代动力学参数估算方法的评估。I. 米氏模型:常规临床药代动力学数据。
J Pharmacokinet Biopharm. 1980 Dec;8(6):553-71. doi: 10.1007/BF01060053.
4
The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.药代动力学数据分析的群体方法:原理与标准数据分析方法
Drug Metab Rev. 1984;15(1-2):153-71. doi: 10.3109/03602538409015063.
5
Experience with NONMEM: analysis of routine phenytoin clinical pharmacokinetic data.NONMEM的应用经验:苯妥英钠常规临床药代动力学数据分析
Drug Metab Rev. 1984;15(1-2):293-303. doi: 10.3109/03602538409015067.
6
Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with Winsorization.群体药代动力学研究中估计不可估计的标准误差:带 Winsor 化的自助法
Eur J Drug Metab Pharmacokinet. 2002 Jul-Sep;27(3):213-24. doi: 10.1007/BF03190460.
7
Estimation of population pharmacokinetic parameters in the presence of non-compliance.存在不依从性情况下的群体药代动力学参数估计
J Pharmacokinet Pharmacodyn. 2003 Feb;30(1):53-81. doi: 10.1023/a:1023297426153.
8
Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model.群体药代动力学参数估计的替代方法:与非线性混合效应模型的比较。
Drug Metab Rev. 1984;15(1-2):265-92. doi: 10.3109/03602538409015066.
9
Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.多柔比星的群体药代动力学:成人和 3 岁以上儿童 NONMEM 模型的建立。
Cancer Chemother Pharmacol. 2013 Mar;71(3):749-63. doi: 10.1007/s00280-013-2069-1. Epub 2013 Jan 13.
10
Population pharmacodynamic modeling and covariate detection for central neural blockade.
Anesthesiology. 1996 Sep;85(3):502-12. doi: 10.1097/00000542-199609000-00009.

引用本文的文献

1
In the Cradle of Pharmacometric Methodology: Introducing Population PKPD Modeling, Simultaneous Analysis, and the Effect-Compartment Model-Commentary on Sheiner et al.在药代动力学方法的摇篮中:介绍群体药代动力学-药效学建模、同步分析和效应室模型——对谢纳等人的评论
Clin Pharmacol Ther. 2025 Jun;117(6):1516-1532. doi: 10.1002/cpt.3663.
2
Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study.基线药物清除率可预测接受维多珠单抗治疗的炎症性肠病儿童的预后:VedoKids前瞻性多中心研究结果
Aliment Pharmacol Ther. 2025 Mar;61(6):1000-1010. doi: 10.1111/apt.18484. Epub 2025 Jan 15.
3

本文引用的文献

1
Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.群体药代动力学参数估算方法的评估。I. 米氏模型:常规临床药代动力学数据。
J Pharmacokinet Biopharm. 1980 Dec;8(6):553-71. doi: 10.1007/BF01060053.
2
The pharmacokinetics of d-tubocurarine in man with and without renal failure.d-筒箭毒碱在有和没有肾衰竭的人体中的药代动力学。
J Pharmacol Exp Ther. 1977 Jul;202(1):1-7.
Population Pharmacokinetic Quantification of CYP2D6 Activity in Codeine Metabolism in Ambulatory Surgical Patients for Model-Informed Precision Dosing.
人口药代动力学定量分析门诊手术患者中可待因代谢中 CYP2D6 活性,以实现基于模型的精准给药。
Clin Pharmacokinet. 2024 Nov;63(11):1547-1560. doi: 10.1007/s40262-024-01433-9. Epub 2024 Oct 23.
4
Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare.推进精准医学:药物研发、临床药理学和个性化医疗中创新的计算机模拟方法综述。
Pharmaceutics. 2024 Feb 27;16(3):332. doi: 10.3390/pharmaceutics16030332.
5
Population Survival Kinetics Derived from Clinical Trials of Potentially Curable Lung Cancers.从潜在可治愈的肺癌临床试验中得出的人群生存动力学。
Curr Oncol. 2024 Mar 20;31(3):1600-1617. doi: 10.3390/curroncol31030122.
6
Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus.多格列艾汀在健康受试者和 2 型糖尿病患者中的群体药代动力学分析。
Clin Pharmacokinet. 2023 Oct;62(10):1413-1425. doi: 10.1007/s40262-023-01286-8. Epub 2023 Aug 3.
7
Individual Components of Polymyxin B Modeled via Population Pharmacokinetics to Design Humanized Dosage Regimens for a Bloodstream and Lung Infection Model in Immune-Competent Mice.通过群体药代动力学模拟多粘菌素 B 的各个成分,为免疫功能正常的小鼠的血流和肺部感染模型设计人性化的剂量方案。
Antimicrob Agents Chemother. 2023 May 17;67(5):e0019723. doi: 10.1128/aac.00197-23. Epub 2023 Apr 6.
8
Input layer regularization for magnetic resonance relaxometry biexponential parameter estimation.输入层正则化在磁共振弛豫双指数参数估计中的应用。
Magn Reson Chem. 2022 Nov;60(11):1076-1086. doi: 10.1002/mrc.5289. Epub 2022 Jun 20.
9
Pharmacometric estimation methods for aggregate data, including data simulated from other pharmacometric models.群体数据的药物代谢动力学估算方法,包括来自其他药物代谢动力学模型模拟的数据。
J Pharmacokinet Pharmacodyn. 2021 Oct;48(5):623-638. doi: 10.1007/s10928-021-09760-1. Epub 2021 Jun 22.
10
An Algorithm for Nonparametric Estimation of a Multivariate Mixing Distribution with Applications to Population Pharmacokinetics.一种用于多元混合分布非参数估计的算法及其在群体药代动力学中的应用
Pharmaceutics. 2020 Dec 30;13(1):42. doi: 10.3390/pharmaceutics13010042.